Back to search

Aristotle University Of Thessaloniki (AUTH)

Κλινικοϊστολογική διερεύνηση και ταξινόμηση δερματικών τοξικοτήτων από ανοσοθεραπεία και επίδραση στην ποιότητα ζωής ογκολογικών ασθενών, βάσει μορφολογίας και βαρύτητας της τοξικότητας

Abstract

dc:description

INTRODUCTION: Immunotherapy based on anti-CTLA-4 and anti-PD-1/PD-L1 immune checkpoint inhibitors (ICIs) has unlocked new possibilities for cancer treatment. Approximately 30% to 50% of patients however develop cutaneous adverse reactions, so timely recognition of immune-mediated skin disorders, their proper classification and prompt treatment are imperative in order to ensure an uninterrupted oncological course for patients. OBJECTIVE: The research objective of this study is to investigate skin adverse reactions to immunotherapy, based on the clinical and histological characteristics of individual rashes, as well as their impact on the patients’ quality of life. The primary objectives were (a) to document similarities and differences in the histological characteristics between the two groups, (b) to assess the impact of cutaneous toxicity on patients’ quality of life, and (c) to evaluate the level of agreement between dermatological quality-of-life assessment tools (DLQI, pNRS) and an oncology reference tool (EORTC-QlQ-C30). A secondary objective was to assess changes in these indices following therapeutic interventions by specialized dermatologists. METHOD: The study group for the primary objective of this study consisted of 35 patients and 70 controls (non-oncology patients with comparable rashes and demographic characteristics). Biopsy specimens were obtained from all 35 patients for eczematous, psoriasiform, lichenoid, and bullous pemphigoid-like rashes and compared by dermatosis category against predominant histological findings from the control group. For the secondary objective, the study included 110 oncology patients with dermatological immune-related adverse events. Patients in this group had a mean age of 67 years and -during three separate visits- were requested to complete questionnaires based on the DLQI (Dermatology Life Quality Index), EORTC-QLQ-C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire) and the Numerical Rating Scale for Itching (pNRS) indices. Clinical presentation, severity and treatment were all recorded, as well as the course of the underlying malignancy and the impact of skin toxicity on oncological treatment. Photographs were taken for both study objectives, both during the initial and follow-up visits. RESULTS: For the first objective of this thesis 35 oncology patients were included, all histologically diagnosed with eczematous (10/35 [28.6%]), psoriasiform (10/35 [28.6%]), lichenoid (10/35 [28.6%]), and bullous eruptions (5/10 [14.8%]), primarily of severity grade 3 (58.8%). Acanthosis was present in high percentages (60%) in lichenoid rashes, while in psoriasiform rashes, subkeratotic pustules and spongiosis were found in comparatively high percentages (80% and 50%, respectively). A tendency toward cell-poor variants of pustular eruptions was also observed. The histology of the eczematous rash was identical to that of the idiopathic form. Regarding the second objective of the thesis -the effect of toxicities on patients’ quality of life- a total of 110 patients participated in the study. The mean (SD) DLQI and pNRS scores were 15.54 (5.44) and 7.25 (2.95) respectively, while the functional, symptomatic, and summary scores of the EORTC-C30 were 79.17 (2.11), 17.66 (3.60), and 80.67 (3.08) respectively. Following therapeutic interventions, there was a statistically significant reduction in DLQI scores after the first intervention compared to the baseline and after the second intervention compared to the first [mean (SD) reduction 4.38 (2.91), p<0.001 and 5.16 (3.99), p<0.001, respectively]. The DLQI showed no correlation with the EORTC-C30 overall health status/Quality of Life (rho 0.01, p=0.90). CONCLUSIONS: Skin immune-mediated adverse reactions from ICIs share common clinical and histological characteristics with the corresponding idiopathic rashes and should be managed accordingly. A clinical-histopathological correlation is required in ambiguous cases. Immune-mediated skin adverse reactions negatively impact the quality of life (QoL) of oncology patients. Dermatological intervention improves patients’ quality of life, facilitating optimal oncological treatment. The poor correlation between the DLQI and the EORTC-QLQ-30 highlights the need for tailored quality of life (QoL) measurement tools in the context of treatment with checkpoint inhibitors.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2026

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Kemanetzi, Christina
  • Κεμανετζή, Χριστίνα

Subjects

dc:subject × 14

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/61789

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kemanetzi, Christina; Κεμανετζή, Χριστίνα. Κλινικοϊστολογική διερεύνηση και ταξινόμηση δερματικών τοξικοτήτων από ανοσοθεραπεία και επίδραση στην ποιότητα ζωής ογκολογικών ασθενών, βάσει μορφολογίας και βαρύτητας της τοξικότητας. Aristotle University Of Thessaloniki (AUTH), 2026. http://hdl.handle.net/10442/hedi/61789